• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Ulster Med J . Chest computed tomography and plain radiographs demonstrate vascular distribution and characteristics in COVID-19 lung disease - a pu

tetano

Editor, Senior Moderator
Ulster Med J


. 2025 Apr;94(1):4-12.
Epub 2025 Apr 30. Chest computed tomography and plain radiographs demonstrate vascular distribution and characteristics in COVID-19 lung disease - a pulmonary vasculopathy

Graham Lloyd-Jones[SUP] 1 [/SUP], James Shambrook[SUP] 2 [/SUP], Alastair Watson[SUP] 3 4 [/SUP], Anna Freeman[SUP] 2 4 5 [/SUP], Tom M A Wilkinson[SUP] 2 4 5 [/SUP]



Affiliations
Abstract

Introduction: Early in the COVID-19 pandemic, CT was demonstrated as a sensitive tool for diagnosing COVID-19. We undertook a detailed study of CT scans in COVID-19 patients to characterise disease distribution within lung parenchyma, respiratory airways, and pulmonary vasculature, aiming to delineate underlying disease processes.
Methods: We characterised acute phase chest CT of 40 participants with COVID-19 from the REACT study, 31 with CT pulmonary angiography (CTPA), 4 with intravenous contrast enhanced CT and 5 with non-intravenous contrast enhanced CT. Participants had neither been vaccinated nor received systemic steroids. We further correlated the distribution of lung parenchymal damage on CT with contemporaneous chest radiographs.
Results: Parenchymal lung damage was found in all subjects. However, airways inflammation was present in only 23% (9) and limited to small areas. Notably, vascular abnormalities were dominant and characterised by dilated peripheral pulmonary vessels supplying areas of lung damage in a gravity-dependent distribution bilaterally in 95% (38), basally in 90% (36), peripherally in 92.5% (37), and posteriorly in 90% (36). Macrothrombosis was demonstrated in 23% (7) of CTPAs. Wedge-shaped peripheral lung damage, resembling areas of pulmonary vascular congestion, were distinct in 53% (21) with or without visible macrothrombosis. Pleural effusions were seen in 28% (11). Notably, lung opacification distribution in 98% of the plain radiographs matched distribution on CT (39).
Conclusion: Our study frames COVID-19 as a pulmonary vasculopathy rather than a more conventional pneumonia which may be important not only for guiding mechanistic study design but also for the development of novel targeted therapeutics.

Keywords: COVID-19; CT imaging; Chest Radiographs; Respiratory Infections; Vasculopathy.

 
Back
Top Bottom